AD
Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamicacid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-de-L-lysine-(CAS: 106612-94-6)
CAS Number
Related Products
![3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione](https://static.chemtradehub.com/structs/871/871700-24-2-c5dd.webp)
5-Bromo-2,4(1H,3H)-pyrimidinedione
CAS Number: 51-20-7
![3-Iodo-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile](https://static.chemtradehub.com/structs/956/956485-59-9-1f04.webp)
4-Benzyloxy-thiobenzamide
CAS Number: 161975-22-0
3-Chloro-N-cyclopentylbenzamide
CAS Number: 349128-33-2
Other Suppliers for Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamicacid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-de-L-lysine-
Basic Information
Molecular Formula
C151H228N40O47
Molecular Weight
3355.67 g/mol
Physical Properties
Water Solubility
Soluble in water at 2mg/ml
Chemical Identifiers
SMILES
C(C1=CNC2=CC=CC=C12)[C@H](NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1NC=NC=1)CC1C=CC=CC=1)CC1C=CC(=CC=1)O)CC1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(N)=N
InChIKey
GCYXWQUSHADNBF-AAEALURTSA-N
Database References
MDL Number
MFCD00167940
FAQ
Glucagon-like peptide 1 (GLP-1) is a cyclic decapeptide with a molecular weight of approximately 1320 Da. It crystallizes in a β-sheet structure. GLP-1 has poor water solubility and is highly reactive, particularly under basic conditions. It can undergo hydrolysis and racemization. For handling, it is typically formulated in a buffer solution to improve solubility and stability.
GLP-1 is synthesized through solid-phase peptide synthesis (SPPS). Commonly, Fmoc chemistry is used, with an overall yield of around 50-70%. The key steps involve peptide coupling, deprotection, and cleavage from the resin. The final product is purified by reverse-phase HPLC to achieve high purity.
GLP-1 is primarily used in the pharmaceutical industry, particularly in diabetes treatment as an incretin mimetic. It is also of interest in the biotechnology sector for therapeutic research. Additionally, GLP-1 derivatives are explored for their potential in neurodegenerative diseases and weight management. However, its use in industries such as polymers or semiconductors is limited due to its biological nature.
Handling GLP-1 requires strict safety protocols. Wear protective gloves, lab coat, and safety glasses. Work in a fume hood to minimize inhalation and skin contact. Store at -20°C or below to maintain stability. Dispose of waste according to local regulations. Always refer to the Safety Data Sheet (SDS) for specific handling and emergency procedures.
Safety Notice
Please verify product specifications and safety data before use. Contact the supplier for detailed safety information.
Always follow proper handling procedures
Contact Information
Contact Person
Fang Rui
wangkang@jskchem.com
Mobile
15221441005
Telephone
15221441005
Visit Website
https://www.jskchem.comAddress
No chemical compound information was provided to translate. Please provide the relevant chemical information for translation.